A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients with Essential Thrombocythemia or Polycythemia Vera who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or who Refuse Standard Therapy

Trial Profile

A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients with Essential Thrombocythemia or Polycythemia Vera who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or who Refuse Standard Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Imetelstat (Primary)
  • Indications Essential thrombocythaemia; Polycythaemia vera
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Geron Corporation
  • Most Recent Events

    • 06 Dec 2016 Results assessing dynamics of telomere length were presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exposition, as reported in a Geron Corporation media release.
    • 06 Dec 2016 Results published in the Geron Corporation Media Release.
    • 08 Dec 2015 Results assessing dynamics of mutation were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top